Harpoon Therapeutics - HARP Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year target prices for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $18.00. On average, they predict the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 961.7% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.

Harpoon Therapeutics' stock was trading at $0.7257 at the beginning of the year. Since then, HARP stock has decreased by 4.8% and is now trading at $0.6907.
View the best growth stocks for 2023 here.

Harpoon Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 387,700 shares, an increase of 60.6% from the February 28th total of 241,400 shares. Based on an average daily trading volume, of 498,900 shares, the short-interest ratio is presently 0.8 days. Approximately 2.0% of the shares of the stock are short sold.
View Harpoon Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our HARP earnings forecast.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its earnings results on Monday, March, 27th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.08. The business earned $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 239.23% and a negative net margin of 212.23%.

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.73%), Renaissance Technologies LLC (1.01%), Levin Capital Strategies L.P. (1.00%), Geode Capital Management LLC (0.65%), Sequoia Financial Advisors LLC (0.18%) and Cutler Group LLC CA (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology, Natalie Sacks and Ronald Hunt.
View institutional ownership trends.

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $0.69.

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $22.87 million and generates $31.92 million in revenue each year. The company earns $-116,720,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.